Lipocine Inc. (LPCN) Given Average Rating of “Strong Buy” by Analysts
Shares of Lipocine Inc. (NASDAQ:LPCN) have received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price objective of $19.75 for the company and are anticipating that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also given Lipocine an industry rank of 113 out of 265 based on the ratings given to its competitors.
A number of research firms recently issued reports on LPCN. Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 target price on shares of Lipocine in a research note on Wednesday, August 10th. HC Wainwright began coverage on Lipocine in a research note on Friday, October 7th. They issued a “buy” rating and a $25.00 target price on the stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/lipocine-inc-lpcn-given-average-rating-of-strong-buy-by-analysts.html
Hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System acquired a new position in shares of Lipocine during the second quarter worth $106,000. BlackRock Investment Management LLC raised its position in shares of Lipocine by 2,370.7% in the second quarter. BlackRock Investment Management LLC now owns 62,707 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 60,169 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Lipocine during the first quarter worth $385,000. DRW Securities LLC acquired a new position in shares of Lipocine during the second quarter worth $443,000. Finally, State Street Corp raised its position in shares of Lipocine by 1,408.9% in the second quarter. State Street Corp now owns 200,679 shares of the specialty pharmaceutical company’s stock worth $609,000 after buying an additional 187,379 shares in the last quarter. 47.22% of the stock is currently owned by institutional investors.
Shares of Lipocine (NASDAQ:LPCN) traded up 1.32% during midday trading on Monday, hitting $3.85. The stock had a trading volume of 389,381 shares. Lipocine has a 12-month low of $2.51 and a 12-month high of $14.80. The stock’s market cap is $70.29 million. The stock has a 50-day moving average price of $3.94 and a 200-day moving average price of $6.34.
Lipocine (NASDAQ:LPCN) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Equities analysts forecast that Lipocine will post ($1.31) earnings per share for the current year.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.